News about Global Pharma

Pfizer signs Agreement with US Government to Lower Drug Costs for American Patients

Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in other developed countries and pricing newly launched medicines at parity with other key developed markets.

Global Pharma | 01/10/2025 | By Dineshwori |  201

Biocon Biologics, Amgen Settle Patent Dispute, Paving Way for US Launch of Denosumab Biosimilars

The agreement with Amgen enables Biocon Biologics to launch denosumab biosimilars Bosaya and Aukelso in the US from October 1, 2025.

Global Pharma | 01/10/2025 | By Dineshwori |  389

Lupin Receives Approval from US FDA for Rivaroxaban for Oral Suspension

Lupin’s Rivaroxaban will be manufactured at the company’s Chhatrapati Sambhajinagar facility.

Global Pharma | 01/10/2025 | By Dineshwori |  314

Nyxoah Expands Its Presence in Middle East

Nyxoah expands in the Middle East (ME) with new centres in Dubai, Kuwait and Abu Dhabi after the first Genio implant.

Global Pharma | 30/09/2025 | By Dineshwori |  138

Kai Beckmann to Lead Merck as CEO and Executive Board Chair

The Board of Partners of E. Merck KG appointed Kai Beckmann as future Chairman of the Executive Board and CEO of Merck. Belén Garijo’s tenure to be completed as planned by end of April 2026.

Global Pharma | 30/09/2025 | By Dineshwori |  239

Lupin Acquires VISUfarma, Strengthens Global Specialty Ophthalmology Business

By integrating VISUfarma’s established commercial operations, Lupin aims to tap into the attractive ophthalmology market.

Global Pharma | 30/09/2025 | By Dineshwori |  183

USA Tariff Policy Puts USD 3.1 Billion of Singapore Pharma Exports at Risk Amid Ongoing Talks

The USA’s new tariff policy threatens approximately USD 3.1 billion worth of Singapore’s pharmaceutical exports, according to Singaporean authorities, with trade discussions between the two nations currently underway.

Global Pharma | 29/09/2025 | By Darshana |  289

Dr. Reddy's, Hetero to Produce Affordable Generic Lenacapavir For HIV Prevention by 2027

Indian pharmaceutical companies Dr. Reddy’s Laboratories and Hetero Labs (Hetero) have signed landmark agreements to manufacture generic versions of lenacapavir, a revolutionary long-acting HIV prevention drug, which will be available at roughly USD 40 per patient per year in low- and middle-income countries (LMICs) starting in 2027.

Global Pharma | 29/09/2025 | By Dineshwori |  577

Copan Diagnostics Invests USD 7 Million to Expand US Manufacturing Footprint

Copan Diagnostics, part of the privately held Italy-based Copan Group, has announced more than USD 7 million in new US manufacturing investments across its facilities in California and Puerto Rico.

Global Pharma | 25/09/2025 | By Dineshwori |  225

US FDA Grants Priority Review for Enhertu + Pertuzumab in HER2+ Metastatic Breast Cancer

The US FDA has granted Priority Review to Enhertu + Pertuzumab for HER2+ metastatic breast cancer, following DESTINY-Breast09 trial results showing a 44 percent reduction in risk of disease progression or death and over three years’ median Progression-Free Survival (PFS), positioning it as a potential new first-line standard of care.

Global Pharma | 25/09/2025 | By Dineshwori |  149